February is American Heart Month. Heart disease is the leading cause of death for both men and women in the U.S. Each year 715,000 Americans suffer from a heart attack and 600,000 die of heart disease.

Cardiovascular Rx category leaders like Novartis’ Entresto, Takeda’s Takhzyro and AZ’s Brilinta know that Feb/March is a peak period for heart disease-related search interest, and they are leveraging advertising channels like Google, Facebook, Instagram, Twitter, Display and TV advertising heading into this key window of opportunity to educate patients and healthcare professionals and help reduce the fatal effects of heart disease.

PranifyRx tracks 12 Cardiovascular Rx brands currently in-market with advertising in February, including:

• 230 live Facebook ads

• 59 live Instagram ads

• 8 live Twitter ads

• Display and TV spots

The 2021 Cardiovascular Digital Ad Report from PranifyRx reveals:

• Which brands are leveraging each channel - plus programmatic tech partners shown by brand to inform your media plans and prepare you to leverage incremental budget opportunity.

• Creative & messaging strategies with insights broken down by brand & channel - to inform your ad messaging optimization strategy

• Category Patent Expirations & Brand Lifestage Analysis - to drive your search and social bidding strategies to maximize reach, prevent artificial bidding wars & minimize cost-per-click escalation

PranifyRx is for innovators in pharma marketing who seek superior, first-look ad intelligence to enable creative and media strategies that drive category leadership.

Sign up here for first-look access to weekly updates on New Advertisers, New Creative Launches, Messaging Themes, Bidding Strategy Shifts and more through the end of March when the Cardiovascular Category peak period concludes until 2H 2021.